Controversial Leadership at the FDA

This chapter explores the implications of the recent appointment of a controversial figure to lead the FDA's Center for Biologics Evaluation and Research, focusing on their critical stance toward vaccines and gene therapies. It examines the resulting public discourse and the potential impact on regulatory practices within the scientific community, emphasizing the importance of nuanced discussions in public health.